ES2563952T3
(es)
|
2004-03-26 |
2016-03-16 |
Sumitomo Dainippon Pharma Co., Ltd. |
Compuesto de 8-oxoadenina 9-sustituido
|
WO2006119061A2
(en)
|
2005-05-02 |
2006-11-09 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
JP2008540396A
(ja)
*
|
2005-05-04 |
2008-11-20 |
ファイザー・リミテッド |
癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体
|
RU2008107972A
(ru)
|
2005-08-01 |
2009-09-10 |
Мерк энд Ко., Инк. (US) |
Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
|
CA2620182A1
(en)
*
|
2005-08-22 |
2007-03-01 |
Dennis A. Carson |
Tlr agonists
|
US20090118263A1
(en)
*
|
2005-09-22 |
2009-05-07 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel Adenine Compound
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
AU2007257423B8
(en)
|
2006-05-31 |
2012-02-16 |
The Regents Of The University Of California |
Purine analogs
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
JP2009542645A
(ja)
*
|
2006-07-05 |
2009-12-03 |
アストラゼネカ・アクチエボラーグ |
Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体
|
US8138164B2
(en)
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US8309540B2
(en)
|
2006-10-24 |
2012-11-13 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
WO2008057209A1
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
WO2008057208A2
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
TW200831105A
(en)
*
|
2006-12-14 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
AU2007335962B2
(en)
|
2006-12-20 |
2012-09-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2510946B1
(en)
|
2007-02-07 |
2015-08-05 |
The Regents of The University of California |
Conjugates of synthetic tlr agonists and uses therefor
|
ATE490249T1
(de)
*
|
2007-02-19 |
2010-12-15 |
Glaxosmithkline Llc |
Purinderivate als immunmodulatoren
|
WO2008114006A1
(en)
*
|
2007-03-19 |
2008-09-25 |
Astrazeneca Ab |
9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
|
DK2132209T3
(da)
*
|
2007-03-19 |
2014-04-14 |
Astrazeneca Ab |
9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7)
|
PE20081887A1
(es)
*
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
EP2138497A4
(en)
*
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
CN101687867B
(zh)
*
|
2007-05-08 |
2013-10-02 |
阿斯利康(瑞典)有限公司 |
具有免疫调节性质的咪唑并喹啉
|
EP2170888B1
(en)
|
2007-06-29 |
2015-04-22 |
Gilead Sciences, Inc. |
Purine derivatives and their use as modulators of toll-like receptor 7
|
CA2693537C
(en)
|
2007-07-17 |
2013-06-25 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis c infections
|
CA2699891C
(en)
|
2007-07-19 |
2013-10-22 |
Nigel Liverton |
Macrocyclic compounds as antiviral agents
|
PE20091156A1
(es)
|
2007-12-17 |
2009-09-03 |
Astrazeneca Ab |
Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
|
US20110054168A1
(en)
*
|
2008-01-17 |
2011-03-03 |
Ayumu Kurimoto |
Method for preparing adenine compound
|
US8865896B2
(en)
|
2008-01-17 |
2014-10-21 |
Astrazeneca Aktiebolag |
Method for preparing adenine compound
|
BRPI0907907A2
(pt)
*
|
2008-02-07 |
2015-07-28 |
Univ California |
Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7
|
US8461107B2
(en)
|
2008-04-28 |
2013-06-11 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
DK2540350T3
(da)
|
2008-07-22 |
2014-08-04 |
Merck Sharp & Dohme |
Kombinationer af en makrocyklisk quinoxalinforbindelse, hvilken er enhcv-ns3-protease-inhibitor med andre hcv-midler
|
UA103195C2
(uk)
*
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
TWI480268B
(zh)
|
2008-12-09 |
2015-04-11 |
Gilead Sciences Inc |
類鐸受體的調節劑
|
WO2010088924A1
(en)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
|
EP2396328A2
(en)
|
2009-02-11 |
2011-12-21 |
The Regents of The University of California |
Toll-like receptor modulators and treatment of diseases
|
US8901132B2
(en)
|
2009-03-13 |
2014-12-02 |
Katholieke Universiteit Leuven, K.U. Leuven R&D |
Thiazolopyrimidine modulators as immunosuppressive agents
|
US20100324060A1
(en)
*
|
2009-06-23 |
2010-12-23 |
Gilead Sciences, Inc. |
Pharmaceutical compositions useful for treating hcv
|
US20100324059A1
(en)
*
|
2009-06-23 |
2010-12-23 |
Gilead Sciences, Inc. |
Pharmaceutical compositions useful for treating hcv
|
AU2010273816B2
(en)
|
2009-06-29 |
2015-07-09 |
Incyte Holdings Corporation |
Pyrimidinones as PI3K inhibitors
|
EP2459582B1
(en)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
SI2477987T1
(en)
*
|
2009-09-14 |
2018-03-30 |
Gilead Sciences, Inc. |
MODULATORS TO TOLL OF LIKE RECEPTORS
|
SI2491035T1
(sl)
*
|
2009-10-22 |
2017-10-30 |
Gilead Sciences, Inc. |
Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
|
WO2011068233A1
(en)
*
|
2009-12-03 |
2011-06-09 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
TW201130842A
(en)
*
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
WO2011075643A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
US20110150836A1
(en)
*
|
2009-12-22 |
2011-06-23 |
Gilead Sciences, Inc. |
Methods of treating hbv and hcv infection
|
CN102844030A
(zh)
*
|
2010-01-29 |
2012-12-26 |
沃泰克斯药物股份有限公司 |
用于治疗丙型肝炎病毒感染的疗法
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
JP6026405B2
(ja)
|
2010-04-30 |
2016-11-16 |
テロルメディクス エセアー |
リン脂質薬物類似体
|
US9050319B2
(en)
|
2010-04-30 |
2015-06-09 |
Telormedix, Sa |
Phospholipid drug analogs
|
GB201012889D0
(en)
|
2010-08-02 |
2010-09-15 |
Univ Leuven Kath |
Antiviral activity of novel bicyclic heterocycles
|
WO2011163195A1
(en)
|
2010-06-21 |
2011-12-29 |
Incyte Corporation |
Fused pyrrole derivatives as pi3k inhibitors
|
GB201015411D0
(en)
|
2010-09-15 |
2010-10-27 |
Univ Leuven Kath |
Anti-cancer activity of novel bicyclic heterocycles
|
CN103370317B
(zh)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
|
DK2651943T3
(en)
|
2010-12-17 |
2017-06-06 |
Sumitomo Dainippon Pharma Co Ltd |
purine derivatives
|
AU2011349844B2
(en)
|
2010-12-20 |
2017-06-01 |
Gilead Sciences, Inc. |
Combinations for treating HCV
|
AR084366A1
(es)
|
2010-12-20 |
2013-05-08 |
Incyte Corp |
N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
JP2014510743A
(ja)
*
|
2011-03-31 |
2014-05-01 |
シェファー、コンスタンツェ |
核酸の非ウイルスの導入のためのパーフルオロ化化合物
|
KR101946499B1
(ko)
|
2011-04-08 |
2019-02-11 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
WO2013014052A1
(en)
|
2011-07-22 |
2013-01-31 |
Glaxosmithkline Llc |
Composition
|
WO2013030750A1
(en)
|
2011-09-01 |
2013-03-07 |
Lupin Limited |
Antiviral compounds
|
PT3196202T
(pt)
|
2011-09-02 |
2019-05-31 |
Incyte Holdings Corp |
Heterociclilaminas como inibidores de pi3k
|
MD4589C1
(ro)
|
2011-09-16 |
2019-03-31 |
Gilead Pharmasset Llc |
Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
|
DE102011116417A1
(de)
|
2011-10-18 |
2013-04-18 |
Kurt Lucas |
Zimtrindenextrakt zur Behandlung von Erkrankungen infolge von induzierten Fehlsteuerungen des angeborenen Immunsystems
|
PL2776439T3
(pl)
|
2011-11-09 |
2018-12-31 |
Janssen Sciences Ireland Uc |
Pochodne puryny do leczenia zakażeń wirusowych
|
CA2858090A1
(en)
*
|
2011-12-20 |
2013-06-27 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders
|
SG11201404475TA
(en)
|
2012-02-10 |
2014-08-28 |
Lupin Ltd |
Antiviral compounds with a dibenzooxaheterocycle moiety
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
SG11201408542VA
(en)
*
|
2012-07-13 |
2015-02-27 |
Janssen Sciences Ireland Uc |
Macrocyclic purines for the treatment of viral infections
|
CA2879617C
(en)
|
2012-08-10 |
2021-05-04 |
Janssen Sciences Ireland Uc |
Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
|
JP6196674B2
(ja)
|
2012-08-24 |
2017-09-13 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC |
ピラゾロピリミジン化合物
|
CN105061567B
(zh)
|
2012-10-10 |
2021-07-20 |
深圳大学 |
免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
|
HUE037064T2
(hu)
|
2012-10-10 |
2018-08-28 |
Janssen Sciences Ireland Uc |
Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
|
ES2655843T3
(es)
|
2012-11-16 |
2018-02-21 |
Janssen Sciences Ireland Uc |
Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
|
EP2922550B1
(en)
|
2012-11-20 |
2017-04-19 |
Glaxosmithkline LLC |
Novel compounds
|
EP2922547B1
(en)
|
2012-11-20 |
2017-03-08 |
Glaxosmithkline LLC |
Novel compounds
|
CA2892218A1
(en)
|
2012-11-20 |
2014-05-30 |
Glaxosmithkline Llc |
Novel compounds
|
MY172166A
(en)
|
2013-01-31 |
2019-11-15 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
EA035174B1
(ru)
|
2013-02-21 |
2020-05-12 |
Янссен Сайенсиз Айрлэнд Юси |
Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8
|
BR112015024411B1
(pt)
*
|
2013-03-29 |
2022-02-22 |
Janssen Sciences Ireland Uc |
Desaza-purinonas macrocíclicas para o tratamento de infeções virais e composição farmacêutica que os compreende
|
WO2014187932A1
(en)
|
2013-05-24 |
2014-11-27 |
Janssen R&D Ireland |
Pyridone derivatives for the treatment of viral infections and further diseases
|
UA117590C2
(uk)
|
2013-06-27 |
2018-08-27 |
ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі |
ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
|
EP3027624B1
(en)
|
2013-07-30 |
2018-09-12 |
Janssen Sciences Ireland UC |
Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
|
AP2016009485A0
(en)
*
|
2014-05-01 |
2016-10-31 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
US9944649B2
(en)
|
2014-05-01 |
2018-04-17 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
AU2015287773B2
(en)
*
|
2014-07-11 |
2018-03-29 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of HIV
|
EP3190113B1
(en)
|
2014-08-15 |
2021-05-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pyrrolopyrimidine compounds used as tlr7 agonist
|
WO2016044182A1
(en)
|
2014-09-16 |
2016-03-24 |
Gilead Sciences, Inc. |
Solid forms of a toll-like receptor modulator
|
PT3236972T
(pt)
|
2014-12-26 |
2021-09-24 |
Univ Emory |
Derivados antivirais n4-hidroxicitidina
|
LT3831833T
(lt)
|
2015-02-27 |
2023-02-27 |
Incyte Holdings Corporation |
Pi3k inhibitoriaus gamybos būdai
|
EA035093B1
(ru)
|
2015-03-04 |
2020-04-27 |
Джилид Сайэнс, Инк. |
4,6-диаминопиридо[3,2-d]пиримидиновые соединения, модулирующие toll-подобные рецепторы
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
JP2018525412A
(ja)
|
2015-08-26 |
2018-09-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
重水素化トール様受容体調節因子
|
CR20180321A
(es)
|
2015-12-15 |
2018-08-21 |
Gilead Sciences Inc |
Anticuerpos neutralizadores del virus de inmunodeficiencia humana
|
BR112017002594A2
(pt)
|
2015-12-17 |
2017-12-19 |
Gilead Sciences Inc |
compostos inibidores de cinase de ligação de tank
|
CN107043380A
(zh)
|
2016-02-05 |
2017-08-15 |
正大天晴药业集团股份有限公司 |
一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
|
WO2017188287A1
(ja)
*
|
2016-04-26 |
2017-11-02 |
大日本住友製薬株式会社 |
置換プリン誘導体
|
WO2017191546A1
(en)
|
2016-05-05 |
2017-11-09 |
Laurus Labs Private Ltd. |
Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
US11738013B2
(en)
|
2016-05-27 |
2023-08-29 |
Gilead Sciences, Inc. |
Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
JP7171444B2
(ja)
|
2016-07-01 |
2022-11-15 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
ウイルス感染治療用のジヒドロピラノピリミジン
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
AU2017320742B2
(en)
*
|
2016-08-29 |
2021-08-05 |
F. Hoffmann-La Roche Ag |
7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
AU2017335205B2
(en)
|
2016-09-29 |
2021-11-04 |
Janssen Sciences Ireland Unlimited Company |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
DK3526323T3
(da)
|
2016-10-14 |
2023-06-26 |
Prec Biosciences Inc |
Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet
|
JP6932394B2
(ja)
*
|
2016-11-11 |
2021-09-08 |
ヘポ ファーマスーティカル カンパニー リミテッド |
含窒素複素環化合物、製造方法、中間体、医薬組成物及び応用
|
AR110768A1
(es)
|
2017-01-31 |
2019-05-02 |
Gilead Sciences Inc |
Formas cristalinas de tenofovir alafenamida
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
CN110650729B
(zh)
|
2017-03-29 |
2024-08-20 |
住友制药株式会社 |
疫苗佐剂制剂
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
US10472361B2
(en)
*
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
US10494370B2
(en)
*
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
AU2018319538B9
(en)
|
2017-08-22 |
2021-05-27 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
JP2021035910A
(ja)
*
|
2017-11-01 |
2021-03-04 |
大日本住友製薬株式会社 |
置換プリン化合物
|
EP3706762A4
(en)
|
2017-12-07 |
2021-09-01 |
Emory University |
N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
|
WO2019118884A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
CA3084569A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CA3085424A1
(en)
|
2017-12-21 |
2019-06-27 |
Sumitomo Dainippon Pharma Co., Ltd. |
Combination drug including tlr7 agonist
|
CN111699187A
(zh)
|
2018-02-12 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
用于治疗和预防病毒感染的新的砜化合物和衍生物
|
MY196582A
(en)
|
2018-02-13 |
2023-04-19 |
Gilead Sciences Inc |
PD-1/PD-L1 Inhibitors
|
CA3091142C
(en)
|
2018-02-26 |
2023-04-11 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
CA3093130C
(en)
|
2018-04-19 |
2023-10-17 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
US11485741B2
(en)
|
2018-04-24 |
2022-11-01 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (TLR7) agonists
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
JP7126573B2
(ja)
|
2018-07-03 |
2022-08-26 |
ギリアード サイエンシーズ, インコーポレイテッド |
HIV gp120を標的化する抗体および使用方法
|
CN112384283B
(zh)
|
2018-07-06 |
2023-08-15 |
吉利德科学公司 |
治疗性的杂环化合物
|
CN112384505A
(zh)
|
2018-07-06 |
2021-02-19 |
吉利德科学公司 |
治疗性的杂环化合物
|
ES2962674T3
(es)
|
2018-07-13 |
2024-03-20 |
Gilead Sciences Inc |
Inhibidores PD-1/PD-L1
|
WO2020022272A1
(ja)
|
2018-07-23 |
2020-01-30 |
公益財団法人ヒューマンサイエンス振興財団 |
インフルエンザワクチンを含む組成物
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
BR112021004590A2
(pt)
|
2018-09-12 |
2021-05-25 |
Silverback Therapeutics, Inc. |
composições para o tratamento de doença com conjugados imunoestimuladores
|
CN111072667A
(zh)
*
|
2018-10-22 |
2020-04-28 |
罗欣药业(上海)有限公司 |
五元或六元杂环并嘧啶类化合物及其用途
|
WO2020086556A1
(en)
|
2018-10-24 |
2020-04-30 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
TW202136261A
(zh)
|
2018-10-31 |
2021-10-01 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
TW202136260A
(zh)
|
2018-10-31 |
2021-10-01 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
AU2020231201A1
(en)
|
2019-03-07 |
2021-08-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
US20220249685A1
(en)
|
2019-06-19 |
2022-08-11 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
CN114245807A
(zh)
|
2019-06-25 |
2022-03-25 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
CA3145791A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
US11497808B2
(en)
|
2019-09-30 |
2022-11-15 |
Gilead Sciences, Inc. |
HBV vaccines and methods treating HBV
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
CA3208912A1
(en)
|
2019-10-18 |
2021-04-22 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
MX2022005123A
(es)
|
2019-10-31 |
2022-05-30 |
Forty Seven Inc |
Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
PE20230376A1
(es)
|
2019-12-24 |
2023-03-06 |
Carna Biosciences Inc |
Compuestos moduladores de la diacilglicerol quinasa
|
EP4097104A1
(en)
|
2020-01-27 |
2022-12-07 |
Bristol-Myers Squibb Company |
1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
|
JP2023512229A
(ja)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
|
EP4097100A1
(en)
|
2020-01-27 |
2022-12-07 |
Bristol-Myers Squibb Company |
1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
|
US20230131192A1
(en)
|
2020-01-27 |
2023-04-27 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
KR20220132590A
(ko)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
|
WO2021154669A1
(en)
|
2020-01-27 |
2021-08-05 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
EP4097102A1
(en)
|
2020-01-27 |
2022-12-07 |
Bristol-Myers Squibb Company |
1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
|
CN115151546A
(zh)
|
2020-01-27 |
2022-10-04 |
百时美施贵宝公司 |
作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物
|
KR20220132601A
(ko)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
|
US11692038B2
(en)
|
2020-02-14 |
2023-07-04 |
Gilead Sciences, Inc. |
Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
|
EP4106819A1
(en)
|
2020-02-21 |
2022-12-28 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
CN115605493A
(zh)
|
2020-03-20 |
2023-01-13 |
吉利德科学公司(Us) |
4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
|
MX2022013619A
(es)
|
2020-05-01 |
2022-11-16 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina que inhiben cd73.
|
AU2021267373A1
(en)
|
2020-05-06 |
2022-12-08 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
|
EP4153181A1
(en)
|
2020-05-21 |
2023-03-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
EP4175673A1
(en)
|
2020-07-01 |
2023-05-10 |
ARS Pharmaceuticals Inc. |
Anti-asgr1 antibody conjugates and uses thereof
|
AU2021320236A1
(en)
|
2020-08-07 |
2023-04-13 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
WO2022063278A1
(zh)
*
|
2020-09-27 |
2022-03-31 |
上海维申医药有限公司 |
大环tlr7激动剂、其制备方法、药物组合物及其用途
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
CN116437958A
(zh)
|
2020-11-11 |
2023-07-14 |
吉利德科学公司 |
鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
|
WO2022140527A1
(en)
|
2020-12-23 |
2022-06-30 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
CN117736210A
(zh)
*
|
2021-01-28 |
2024-03-22 |
上海翊石医药科技有限公司 |
一类芳杂环类化合物及其制备方法和用途
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
JP2024516631A
(ja)
|
2021-04-23 |
2024-04-16 |
プロファウンドバイオ ユーエス カンパニー |
抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
|
US20240269142A1
(en)
|
2021-05-13 |
2024-08-15 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
JP2024520593A
(ja)
|
2021-06-23 |
2024-05-24 |
ギリアード サイエンシーズ, インコーポレイテッド |
ジアシルグリエルコール(diacylglyercol)キナーゼ調節化合物
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
AU2022376954A1
(en)
|
2021-10-29 |
2024-05-02 |
Gilead Sciences, Inc. |
Cd73 compounds
|
TW202334139A
(zh)
|
2021-11-09 |
2023-09-01 |
美商雅捷可斯治療公司 |
作為jak2抑制劑之6-雜芳氧基苯并咪唑及氮雜苯并咪唑
|
AU2022401696A1
(en)
|
2021-12-03 |
2024-05-09 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
KR20240117588A
(ko)
|
2021-12-03 |
2024-08-01 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 바이러스 감염 치료용 화합물
|
KR20240113832A
(ko)
|
2021-12-03 |
2024-07-23 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 바이러스 감염 치료용 화합물
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
EP4245756A1
(en)
|
2022-03-17 |
2023-09-20 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
TWI843506B
(zh)
|
2022-04-06 |
2024-05-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
TW202400138A
(zh)
|
2022-04-21 |
2024-01-01 |
美商基利科學股份有限公司 |
Kras g12d調節化合物
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024006982A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
US20240083984A1
(en)
|
2022-08-26 |
2024-03-14 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024076915A1
(en)
|
2022-10-04 |
2024-04-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
WO2024137852A1
(en)
|
2022-12-22 |
2024-06-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|